Journal of Pharmacological Research and Developments
e-ISSN: 2582-0117
Volume-5, Issue-2 (July-December, 2023)

www.matjournals.com

The Role of Epigenetic Modifications in Drug Response and Resistance

Abhinandan Patil[1*], Shrihari Kulkarni[2], Ashutosh Upadhye[3], Chandraprabhu Jangme[4], Ketaki Dhane[4]
[1]Associate Professor, D. Y. Patil Education Society, (Deemed to be University), Kolhapur, Maharashtra, India
[2]HOD, Department of Biotechnology, Vivekanand College, (Autonomous) Kolhapur, Maharashtra, India
[3]Faculty, Department of Biotechnology, Vivekanand College, (Autonomous) Kolhapur, Maharashtra, India
[4]Professor, D. Y. Patil Education Society, (Deemed to be University), Kolhapur, Maharashtra, India

[*]Correspondence Author: abhisirdyp@gmail.com

Received Date: May 24, 2023 *Published Date: July 18, 2023*

ABSTRACT

The inability of epigenetic modifications to control gene expression has been related to a variety of diseases and conditions, including cancer and neurological ailments, amongst others. In recent years, there has been a rise in the amount of attention in pharmacology that is focused on the role that epigenetic modifications play in the response to medicine and the development of drug resistance. This concise review will attempt to provide a synopsis of what is currently known on the influence that epigenetic changes have on the treatment efficacy and resistance mechanisms of various diseases. DNA methylation, histone modifications, and non-coding RNAs are some of the key epigenetic markers that are covered in this article in relation to their function in the pharmacokinetics and pharmacodynamics of drugs. In addition, we highlight the development of approaches that attempt to enhance treatment outcomes while simultaneously overcoming drug resistance by targeting epigenetic alterations. A fundamental understanding of the connection between epigenetics and pharmacological response is required for the development of individualized treatment plans and the identification of novel therapeutic targets.

Keywords- Biomarkers, Drug resistance, Epigenetics, Neuroinflammation, Pharmacodynamics, Pharmacokinetics

INTRODUCTION

Different disease situations can be affected by epigenetic alterations because of their involvement in controlling gene expression patterns and altering cellular functioning. Alterations in gene expression can be inherited and do not entail changes to the DNA sequence [1-3]. Gene expression is dynamically regulated in response to environmental stimuli in part through epigenetic processes such as DNA methylation, histone changes, and non-coding RNAs. Cancer, neurological illnesses, cardiovascular diseases, and autoimmune ailments are only some of the diseases that have been shown to have links to aberrant epigenetic patterns in their development and progression. In particular, pharmacologists have been very curious about how epigenetic alterations affect drug response and resistance. To improve treatment options and provide tailored medicine, knowing how epigenetics affect medication responses is essential. Directly affecting therapeutic effectiveness, epigenetic alterations can affect the expression of drug targets, drug-metabolizing enzymes, and drug transporters. Furthermore, medication resistance can be induced by epigenetic changes, leading to unsuccessful therapy and further disease development [3-5].

The purpose of this brief review is to summarize what is currently known about the impact of epigenetic changes on therapeutic effectiveness and resistance mechanisms. Drug reactions will be discussed about DNA methylation, histone changes, and non-coding RNAs. We'll also talk about the latest methods

for addressing drug resistance and improving treatment results by focusing on epigenetic changes.

The key to improving patient outcomes and reducing unwanted side effects of therapy is a deeper understanding of the intricate relationship between epigenetic changes and medication responsiveness.

Epigenetic Alterations and the Control of Genes

Epigenetic alterations are crucial for development, cellular differentiation, and maintaining cellular identity because of their involvement in regulating gene expression. Chemical alterations to the DNA molecule and its associated proteins can have long-lasting impacts on gene function without changing the DNA sequence itself. Epigenetic alterations play a role in the fine-tuning of gene expression programs in response to environmental stimuli and developmental signals by dynamically modifying chromatin structure and accessibility. DNA methylation, which normally takes place at cytosine residues inside CpG dinucleotides, is one of the key epigenetic processes involved in gene regulation. When CpG islands in gene promoters are methylated, transcription factors and other regulatory proteins are unable to bind, leading to gene silence. Gene activation and transcriptional activity can be facilitated, on the other hand, when gene promoters are hypomethylated [6-10].

Acetylation, methylation, phosphorylation, and ubiquitination are only a few examples of histone modifications that play an important role in gene regulation. The nucleosome, the smallest unit of chromatin, is where these alterations take place on the amino-terminal tails of histone proteins. Markers for diverse chromatin states are the different combinations of histone modifications, which determine the degree to which DNA is accessible to transcription factors and other regulatory proteins. For instance, acetylation of histone tails is commonly linked to accessible chromatin and vigorous gene transcription, but methylation can have a wide range of consequences depending on the methylated residue and its degree. Non-coding RNAs (ncRNAs) have been shown to play an important role in gene regulation with DNA methylation and histone modifications. MicroRNAs, long non-coding RNAs, and tiny interfering RNAs are all examples of non-coding RNAs that interact with messenger RNAs (mRNAs) to alter the stability, translation, and expression of the mRNAs they target. Non-coding RNAs can regulate gene expression and other cellular activities by interacting with messenger RNAs. Deciphering the molecular processes behind cellular functioning and disease aetiology relies on our ability to comprehend the intricate relationship between epigenetic changes and gene regulation. Understanding the ever-changing relationships between epigenetic changes and the genes they regulate will expand our understanding of fundamental biological processes and may lead to the identification of new treatment targets for a wide range of disorders [11-15].

The Role of Epigenetics in the Development of Illness

The role of epigenetics in the etiology of neurological illnesses is substantial. Neuronal gene expression, synaptic plasticity, and neuroinflammation can all be affected by aberrant DNA methylation and histone changes, which in turn can contribute to diseases including Alzheimer's, Parkinson's, and schizophrenia. Insight into disease processes and new therapy avenues can be gained by investigating the epigenetic variables contributing to various illnesses. Epigenetic alterations have also been linked to the development of chronic illnesses such as diabetes, autoimmunity, and cardiovascular disease. The expression of genes involved in inflammation, lipid metabolism, and oxidative stress can be altered by changes in DNA methylation patterns and histone modifications, which can contribute to the onset and progression of illness. Disease aetiology is not the only arena in which epigenetics has importance. Biomarkers for illness diagnosis, prognosis, and therapy response can be found in epigenetic modifications, paving the way for precision medicine. The potential for preventative treatments and new understandings of gene-environment interactions can be gained from research into the effects of environmental variables on epigenetic alterations [16-19].

Epigenetics research has uncovered its wide-ranging importance in the pathophysiology of diseases. To better manage diseases and enhance patient outcomes, epigenetic modifications should be studied and understood to shed light on underlying molecular mechanisms, and direct treatment tactics, and pave the way for the creation of personalized medicine techniques.

EPIGENETIC ALTERATIONS AND THE REACTION TO DRUGS

Drug Effectiveness and DNA Methylation

Adding a methyl group to DNA is an epigenetic alteration that plays a crucial function in controlling gene expression. By affecting the expression levels of drug targets, drug-metabolizing enzymes, and drug transporters, it can significantly affect medication effectiveness. The methylation status of particular promoter regions of genes controls whether or not they are expressed. DNA methylation can have a direct impact on the expression of pharmacological targets, such as receptors or enzymes in the drug response pathway, and hence on medication effectiveness. Silencing of therapeutic target genes due to hypermethylation of gene promoters can decrease treatment effectiveness. The inactivation of tumour suppressor genes and subsequent resistance to anticancer treatments has been linked to hypermethylation of their promoter regions. DNA methylation can affect drug-metabolizing enzymes and drug transporters, therefore influencing drug pharmacokinetics and pharmacodynamics. Changes in drug metabolism and clearance can result from methylation of the promoters of drug-metabolizing enzymes such as cytochrome P450 enzymes. DNA methylation, in a similar vein, can control the expression of drug transporters, so affecting drug uptake, distribution, and clearance. Medication development and customized treatment can both benefit from a deeper understanding of the correlation between DNA methylation and how well a medication works. DNA methylation is only one example of an epigenetic change that has the potential to be used as a biomarker for gauging patient response to therapy and tailoring care. It is also possible to investigate the possibility of modulating therapeutic efficacy and overcoming drug resistance by targeting DNA methylation with particular medicines, such as DNA demethylating agents [20-24].

The expression of therapeutic targets, drug-metabolizing enzymes, and drug transporters are all affected by DNA methylation, which, in turn, has a major impact on medication effectiveness. Understanding how DNA methylation affects drug response pathways might pave the way for more targeted treatments and better patient outcomes across a wide range of diseases.

Chromatin Rearrangements and Alterations to Histones

The control of gene expression and the dynamic organization of chromatin structure rely heavily on histone modifications and chromatin remodelling. Development, differentiation, and the pathogenesis of illness are just a few of the cellular processes that depend on these epigenetic alterations. Histone proteins are modified in their amino-terminal tails by acetylation, methylation, phosphorylation, and ubiquitination. These alterations can change the way chromatin is structured, which in turn affects how easily DNA can be accessed by the transcription machinery. Histone acetyltransferases (HATs) acetylate histone tails, leading to a less rigid chromatin structure and increased ease of gene transcription. On the other hand, histone deacetylases (HDACs) function by removing acetyl groups from histones, leading to a more compacted chromatin state and ultimately suppressing genes. The particular residue and level of methylation determine the effects of methylation on histones. In general, methylation of H3K9 and H3K27 is related to gene repression, while methylation of H3K4, H3K36, and H3K79 is connected to active gene transcription. Histone methyltransferases (HMTs) and histone demethylases (HDMs) add or remove methyl groups from histones [25-28].

Chromatin modification and gene regulation also benefit from histone phosphorylation and ubiquitination. To modify transcriptional activity, histone phosphorylation can modify histones' connections with other chromatin-associated proteins. By enlisting particular protein complexes or signalling pathways, the ubiquitination of histones can alter chromatin structure and gene expression. The accessibility of DNA to the transcriptional

machinery is regulated in a context-dependent fashion by a combination of histone modifications and chromatin remodelling. Cancer, neurological problems, and cardiovascular illnesses are only some of the conditions that may be exacerbated by a disruption in these processes. Insights into disease causes and prospective therapeutic intervention targets can be gained by gaining a deeper understanding of the complex interaction between histone changes, chromatin remodelling, and gene regulation [29].

Finally, chromatin remodelling and histone alterations are critical processes for controlling gene expression and preserving cellular identity. There are many biological processes, including those related to health and illness, in which these epigenetic processes play crucial roles. Our knowledge of gene regulation will be enhanced, and new treatment approaches to a variety of diseases may be uncovered, if we can learn more about the dynamic nature of histone modifications and their functional repercussions.

The Role of Non-Coding RNAs in Drug Responsiveness

Key regulators of gene expression and influential in treatment response and effectiveness, non-coding RNAs (ncRNAs) have recently come into the spotlight. These non-coding RNAs (ncRNAs) are involved in a wide range of biological functions despite not being able to code for proteins themselves. Their aberrant regulation can affect pathways involved in the body's response to drugs, perhaps contributing to resistance mechanisms. The tiny noncoding RNAs known as microRNAs (miRNAs) have been linked to changes in medication responsiveness and sensitivity. Target mRNAs can be degraded or suppressed in translation once miRNAs attach to them. The expression of drug targets, drug-metabolizing enzymes, and drug transporters can be affected by miRNAs because of their interactions with mRNAs. Drug resistance has been linked to the altered expression of certain miRNAs in several malignancies and other disorders. Another group of ncRNAs involved in drug response is the long non-coding RNAs (lncRNAs) [29-33]. Long non-coding RNAs (lncRNAs) can regulate gene expression by interacting with chromatin and transcription factors. Apoptosis, cell cycle control, and DNA repair are only some of the biological processes that can be affected by lncRNA dysregulation, which has been linked to drug resistance. In addition to their role as diagnostic tools, small interfering RNAs (siRNAs) have therapeutic potential by silencing disease-related genes. These siRNAs present a promising technique for overcoming drug resistance and improving therapeutic response, since they may be tailored to target specific disease-associated genes or components involved in drug resistance. To improve treatment plans and provide more individualized medicine, we need a deeper knowledge of how ncRNAs affect medication responses. To better predict medication response and personalize treatment, ncRNAs may be used as biomarkers. Drug effectiveness and resistance mechanisms can be improved and circumvented by targeting specific ncRNAs or using ncRNAs as therapeutic agents [18, 19, 34-39].

In conclusion, ncRNAs, such as microRNAs, long noncoding RNAs, and small interfering RNAs, have a major impact on the regulation of drug response and drug resistance. They contribute to the complexity of therapeutic effectiveness by interacting with target mRNAs, participating in regulatory networks, and influencing cellular processes. Improved treatment results and more individualized medication therapy might result from more investigation into ncRNA-mediated processes and the development of novel therapeutic techniques targeting ncRNAs. The methylation status of specific gene promoter regions can determine whether a gene is active or silenced. In the context of drug efficacy, DNA methylation can directly affect the expression of drug targets, such as receptors or enzymes involved in drug response pathways. Hypermethylation of gene promoters can lead to the silencing of drug target genes, resulting in reduced drug efficacy. For example, hypermethylation of the promoter region of tumour suppressor genes can lead to their inactivation and decreased sensitivity to anticancer drugs. In addition to drug targets, DNA methylation can also impact drug-metabolizing enzymes and drug transporters, affecting the pharmacokinetics and pharmacodynamics of drugs. Methylation of the promoters of drug-metabolizing enzymes, such as cytochrome P450 enzymes, can alter their expression levels, leading to changes in drug metabolism and clearance. Similarly, DNA methylation can regulate the expression of drug

transporters, influencing drug absorption, distribution, and elimination. Understanding the relationship between DNA methylation and drug efficacy has important implications for personalized medicine and drug development. Epigenetic modifications, including DNA methylation, can serve as potential biomarkers for predicting drug response and individualizing treatment approaches. Moreover, targeting DNA methylation with specific drugs, such as DNA demethylating agents, can be explored as a strategy to modulate drug efficacy and overcome drug resistance [29-34].

In conclusion, DNA methylation plays a crucial role in drug efficacy by modulating the expression of drug targets, drug-metabolizing enzymes, and drug transporters. Elucidating the impact of DNA methylation on drug response pathways can facilitate the development of personalized medicine approaches and strategies to optimize therapeutic outcomes in various disease contexts.

MODIFICATIONS TO THE EPIGENOME AS A CAUSE OF DRUG RESISTANCE

Acquired Medication Resistance and Epigenetic Alterations

Several biological pathways, including epigenetic alterations, contribute to the problem of acquired drug resistance in cancer treatment. By altering gene expression patterns and cellular signalling networks, epigenetic changes play a critical role in the emergence of drug resistance. Acquired drug resistance is often the result of epigenetic modifications, and understanding these changes can provide light on the underlying processes and help direct the development of new treatment approaches. DNA methylation is a frequent epigenetic change associated with acquired drug resistance. Tumour suppressor genes and genes implicated in drug response pathways are particularly vulnerable to inactivation due to hypermethylation of gene promoter regions. In glioblastoma, for instance, resistance to alkylating drugs has been linked to hypermethylation of the promoter region of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT). Similarly, endocrine treatment resistance in breast cancer can be caused by hypermethylation of the promoter region of the estrogen receptor gene. Reduced drug target expression, compromised DNA repair processes, and altered cellular responses to treatment can all result from epigenetic alterations [16, 26-29].

Acquired drug resistance is related to changes in histone modifications. Chromatin structure and gene expression can be influenced by changes in histone acetylation, methylation, and phosphorylation. For instance, drug-resistant cancer cells have been found to have elevated histone deacetylase (HDAC) activity, leading to hypoacetylation of histones. This epigenetic alteration can cause chromatin compaction and decreased transcription factor access to target genes, both of which play a role in drug resistance. In addition, methylation marks on particular histones, such as H3K9 methylation, have been linked to resistance to chemotherapeutic drugs in some forms of cancer. Acquired drug resistance has also been linked to non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Modulating the expression of genes involved in drug metabolism, apoptosis, and cell cycle control, miRNA dysregulation can affect drug responsiveness. MiR-21, for example, is linked to resistance to several chemotherapeutic drugs and is just one of several miRNAs shown to regulate drug resistance. Through their interactions with chromatin, transcription factors, and signalling pathways, lncRNAs have also been implicated in acquired drug resistance. Fortunately, therapeutic interventions can reverse the epigenetic alterations that contribute to acquiring drug resistance. Several epigenetic modifiers have shown promise in re-sensitizing drug-resistant cells to treatment. These include DNA demethylating drugs, histone deacetylase inhibitors, and small molecule inhibitors of particular lncRNAs. Acquired medication resistance can be more easily overcome and treatment results can be improved by using a combination approach that targets both genetic and epigenetic changes [7-10, 17-19, 31-35].

In conclusion, acquired drug resistance is closely linked to epigenetic alterations such as DNA methylation, histone modifications, and dysregulation of non-coding RNAs. This leads to diminished medication sensitivity and treatment failure as a result of changes in gene expression patterns and cellular signalling networks. To improve patient outcomes across a wide range of disorders, understanding the epigenetic processes causing acquired drug resistance is essential. Drug efflux pumps and drug

metabolism enzymes are two essential mechanisms that regulate drug disposition and reaction in cells and tissues, and epigenetic regulation plays a significant role in altering the expression and activity of these factors. Changes in medication pharmacokinetics and therapeutic outcomes may result from epigenetic changes that affect the expression of drug transporters and metabolic enzymes, such as DNA methylation, histone modifications, and non-coding RNA-mediated processes.

Cancer Heterogeneity and Clonal Evolution: The Role of Epigenetic Alterations

The elimination of pharmaceuticals from cells and tissues through drug efflux pumps, such as ATP-binding cassette (ABC) transporters, has a major impact on drug bioavailability and intracellular drug concentrations. Drug efflux and cellular drug sensitivity can be affected by epigenetic alterations that alter the expression of ABC transporters. P-glycoprotein (encoded by the ABCB1 gene) and multidrug resistance-associated protein 1 (encoded by the ABCC1 gene) are two examples of ABC transporters whose expression has been demonstrated to be regulated by DNA methylation. Reduced drug efflux, higher drug accumulation, and enhanced drug responsiveness can occur from hypermethylation of the promoter regions of these genes. Epigenetic modulation of drug efflux pumps includes alterations to histones. The accessibility of transcription factors to the promoter regions of ABC transporter genes can be regulated by acetylation and methylation of histones. Increased expression and sensitivity of cancer cells to chemotherapeutic treatments have both been linked to the use of histone deacetylase (HDAC) inhibitors, which increase the acetylation of histones associated with ABC transporter gene promoters. Similarly, cytochrome P450 (CYP) enzymes, which are crucial in drug metabolism and disposal, can be affected by epigenetic changes. The expression of CYP enzymes may be controlled by DNA methylation and histone changes. Gene silence can occur when CYP promoters are methylated, and histone alterations can alter the levels of accessibility to transcription factors and RNA polymerase [24, 31]. Drug responsiveness and treatment effectiveness can vary because of epigenetic alterations that alter the expression of CYP enzymes. Also, non-coding RNAs, especially microRNAs (miRNAs), can regulate drug expression by directing the destruction or translational suppression of mRNAs encoding drug efflux pumps and drug metabolism enzymes. Destabilization or translational inhibition of target mRNAs can occur when miRNAs bind to their 3' untranslated regions (UTRs). Different miRNAs have been shown to control medication efflux (through ABC transporters) and metabolism (via CYP enzymes). Changes in medication responsiveness and treatment outcomes may result from the dysregulation of these miRNAs. Drug efflux pumps and drug metabolism enzymes are epigenetically regulated, and understanding this is essential for personalized medicine and drug therapy optimization. Modulating drug transport and metabolism by targeting epigenetic machinery, such as DNA methylation and histone changes, shows promise for improving medication effectiveness and reducing drug resistance. In addition, the discovery of miRNAs that play a role in controlling drug disposition pathways may open up novel avenues for therapeutic intervention [25, 36].

In conclusion, epigenetic control is crucial in affecting drug disposition and response by modifying drug efflux pumps and drug metabolism enzymes. Drug pharmacokinetics and treatment outcomes can be affected by epigenetic alterations such as DNA methylation, histone modifications, and non-coding RNA-mediated processes. Understanding the role of epigenetic processes in drug transport and metabolism might lead to new approaches for enhancing therapeutic performance.

Epigenetic Control of Efflux Pumps and Metabolic Drug Clearance

The use of epigenetic therapy has shown great promise as a method for treating a wide range of ailments, from cancer to neurological problems. Restoration of regular gene expression patterns and triumph over disease-related epigenetic changes are the goals of these treatments, which focus on reversible modifications of DNA and histones. Growing attention has been paid in recent years to the possibility of combining epigenetic therapy with other therapeutic approaches. Epigenetic indicators can also be used to track how well a

treatment is working overtime. DNA methylation patterns and microRNA expression profiles can be monitored over time to offer useful data on treatment efficacy and guide therapeutic decisions or reveal causes of resistance. However, there are still various obstacles that must be overcome before epigenetic biomarkers may be successfully implemented in clinical practice [7-17, 28-34]. These include the creation of reliable and repeatable assays and the standardization of sample collection, processing, and analysis processes. In addition, more study is required to confirm these biomarkers' clinical relevance across a variety of disorders and treatment modalities.

In conclusion, epigenetic indicators present an attractive option for disease-specific patient stratification. Dysregulation of DNA methylation, histones, and non-coding RNAs all yield informative results.

EPIGENETIC MODIFICATIONS AS A TARGET FOR DRUG RESISTANCE OVERCOME

Therapeutic Strategies that Integrate Epigenetic Modifications

Recently, targeting epigenetic changes has been seen as a potentially effective method for treating a wide range of illnesses. However, various obstacles must be overcome before the therapeutic promise of epigenetic targeting may be completely utilized. At the same time, though, these difficulties might be seen as openings for growth and development. Specificity is a major obstacle in addressing epigenetic changes. It is difficult to specifically target disease-associated abnormalities in epigenetics while retaining normal cellular functioning because epigenetic modifications are dynamic and context-dependent. The off-target effects and toxicity that might result from the promiscuous targeting of epigenetic regulators are not to be taken lightly. To reduce the risk of side effects and improve the therapeutic benefit, it is essential to develop methodologies and drugs that selectively adjust certain epigenetic marks or target disease-specific epigenetic changes. The complexity and interdependence of epigenetic regulatory networks present additional difficulties. Gene expression is regulated in a coordinated fashion by epigenetic alterations such as DNA methylation, histone modifications, and non-coding RNA dysregulation. There may be unanticipated effects on other epigenetic marks or cellular functions if this network is disrupted. Targeted treatments that accomplish the desired therapeutic outcomes with minimal side effects require a thorough understanding of the interconnection and cross-talk between various epigenetic alterations [17, 25]. Another major obstacle is the diversity of epigenetic changes within and across illnesses. Depending on the kind of cell, the stage of the disease, and the patient population, epigenetic alterations may take a variety of forms. Finding and treating the precise epigenetic changes that apply to a certain disease subtype or patient population is essential for successful therapy. Because of this, accurate diagnostic methods and patient stratification procedures that take into account individuals' particular epigenetic patterns are urgently needed. Furthermore, there are advantages and disadvantages to epigenetic alterations because of their reversible nature. While reversibility provides hope for therapeutic intervention, it also raises questions about how long treatments should last, how much medication should be given, and whether or not the effects will last permanently. Long-term therapeutic advantages from epigenetic-targeted medicines require achieving effects that are both persistent and permanent. In addition, improving treatment results depends on learning the causes of resistance to epigenetic treatments and creating techniques to overcome resistance whereas nowadays probiotics are used as the line of choice [13, 33- 39].

Despite these obstacles, there is promising potential to target epigenetic alterations. Modulating gene expression via epigenetic processes permits the pursuit of hitherto undruggable targets. Therapeutic possibilities for many illnesses may lie in the ability of epigenetic treatments to reactivate tumour suppressor genes, mute oncogenes, and restore normal gene expression patterns. In addition, because epigenetic alterations are both dynamic and reversible, they can be used in precision medicine. Real-time monitoring and manipulation of epigenetic markers pave the way for patient-specific treatment plans based on their epigenetic profiles. Opportunities for the complete characterization of epigenetic landscapes and the discovery of novel epigenetic targets have arisen with the development of tools

like high-throughput sequencing, epigenomic profiling, and computational biology. The detection of epigenetic modifications in a patient's case can be aided by the integration of multi-omics data and the construction of prediction models. To overcome the obstacles and use the full potential of epigenetic targeting, collaboration and multidisciplinary research are important. To improve the translation of epigenetic research into clinical applications, it is important to bring together experts from molecular biology, computational biology, clinical research, and pharmaceutical sciences [11, 15-21].

In conclusion, there is much hope that many illnesses can be treated by focusing on epigenetic alterations. While there are obstacles, such as the need for precision, the complexity of epigenetic networks, the diversity of epigenomes, and the inability to undo changes, there are also chances for growth and development.

Patient Categorization using Epigenetic Biomarkers

Recent years have seen tremendous development in the science of epigenomics, which has yielded important insights into the function of epigenetic alterations in the etiology and therapy of illness. The use of epigenomics in medication development has the potential to completely transform how treatments are developed and delivered to patients. New possibilities for finding new pharmacological targets, creating targeted therapeutics, and refining treatment regimens have emerged with a deeper comprehension of epigenetic processes and their effect on gene expression. By incorporating epigenomics into the drug development process, hitherto undruggable genes and pathways may be located and targeted. Epigenetic changes can control the expression of disease-related genes [26]. Tumour suppressor genes can be turned on, oncogenes can be turned off, and normal gene expression patterns may be restored by manipulating these epigenetic markers selectively. This paves the way for the creation of medicines that interfere with disease-related gene regulation networks by targeting specific epigenetic changes [26]. Patient-specific biomarkers that help direct treatment decisions and enhance patient stratification are also discovered more easily when epigenomics is incorporated into the drug discovery process. Disease subtypes, prognosis, treatment response, and possible resistance mechanisms may all be predicted using epigenetic modifications as biomarkers. Epigenomic profiling and analysis of epigenetic markers allow for personalized medicine that improves therapeutic results and reduces adverse effects. Drug response and resistance mechanisms can be better understood with the help of epigenomics [8]. In addition to contributing to treatment resistance, epigenetic changes can also affect the success of therapeutic therapies. The development of combination medicines and tactics to overcome resistance can benefit from a deeper understanding of the epigenetic processes controlling drug responsiveness and resistance. Integrating epigenomic data with genomic and transcriptome information gives a more complete picture of the molecular underpinnings of medication response.

CONCLUSION AND PROSPECTS FOR THE FUTURE

In addition, epigenomic profiling may be used at the outset of drug discovery to help identify and rank possible therapeutic targets. It is now feasible to discover genes and pathways that are dysregulated in disease states by mapping the epigenetic landscapes of disease-relevant tissues and cell types. Increase the likelihood of a successful translation into clinical applications by using this data to influence the development of targeted medicines and the design of preclinical trials. The use of epigenomics in the process of developing new medicines has also benefited from technical progress. Genome-wide profiling of epigenetic markers is now possible because to high-throughput sequencing methods like chromatin immunoprecipitation sequencing (ChIP-seq) and bisulfite sequencing. Large-scale epigenomic datasets may now be analyzed and interpreted with the use of computational tools and algorithms, making it easier to detect epigenetic modifications and understand their functional significance. These developments equip scientists with the means to successfully use epigenomics in drug discovery processes.

In conclusion, there are significant prospects for expanding therapeutic methods and bettering patient care through the incorporation of epigenomics in drug discovery and development.

Epigenetic processes that allow for the regulation of gene expression open up new doors for the investigation of previously untreatable genes and pathways. Epigenomic profiling paves the way for the discovery of diagnostic biomarkers and the fine-tuning of therapeutic approaches for individual patients. Furthermore, the creation of combination medicines and tactics to overcome resistance is facilitated by knowledge of the epigenetic processes controlling drug response and resistance. Integration of epigenomics in drug discovery and development is shaping the future of precision medicine and tailored therapeutics, and this trend will only increase with time, money, and effort invested in research and development.

Conflict of Interest: The authors declare no conflict of interest.

Funding: This research received no external funding.
Acknowledgements: The authors would like to thank the reviewers for their valuable feedback and comments on this mini-review.

REFERENCES

1. C Dupont, D. Randall Armant and C A. Brenner (2009). Epigenetics: Definition, mechanisms and clinical perspective, *Seminars in Reproductive Medicine*, 27(5), 351-357, Available at: https://doi.org/10.1055%2Fs-0029-1237423.
2. S L Berger, T Kouzarides, R Shiekhattar and A Shilatifard (2009). An operational definition of epigenetics, *Genes & Development*, 23(7), 781-783, Available at: https://doi.org/10.1101/gad.1787609.
3. B Jin, Y Li and K D Robertson (2011). DNA methylation: superior or subordinate in the epigenetic hierarchy?, *Genes & Cancer*, 2(6), 607-617, Available at: https://doi.org/10.1177/1947601910393957.
4. A Sumarpo, K Ito, Y Saiki, et al (2020). Genetic and epigenetic aberrations of ABCB1 synergistically boost the acquisition of taxane resistance in esophageal squamous cancer cells, *Biochemical and Biophysical Research Communications*, 526(3), 586-591, Available at: https://doi.org/10.1016/j.bbrc.2020.03.114.
5. D D Lee, R Leão, M Komosa, et al (2019). DNA hypermethylation within TERT promoter upregulates TERT expression in cancer, *Journal of Clinical Investigation*, 129(1), 223-229, Available at: https://doi.org/10.1172/jci121303.
6. X Yang, H Han, D D De Carvalho, et al (2014). Gene body methylation can alter gene expression and is a therapeutic target in cancer, *Cancer Cell*, 26(4), 577-590, Available at: https://doi.org/10.1016/j.ccr.2014.07.028.
7. M Ahmad Malla, A Dubey, A Kumar, et al (2023). Optimization and elucidation of organophosphorus and pyrethroid degradation pathways by a novel bacterial consortium C3 using RSM and GC-MS-based metabolomics, *Journal of the Taiwan Institute of Chemical Engineers*, 144, Available at: https://doi.org/10.1016/j.jtice.2023.104744.
8. N Munot, U Kandekar, C Rikame, et al (2022). Improved mucoadhesion, permeation and in vitro anticancer potential of synthesized thiolated acacia and karaya gum combination: A systematic study, *Molecules*, 27(20), Available at: https://doi.org/10.3390/molecules27206829.
9. N Munot, U Kandekar, P S Giram (2022). A comparative study of quercetin-loaded nanocochleates and liposomes: formulation, characterization, assessment of degradation and in vitro anticancer potential, Pharmaceutics, 14(8), Available at: https://doi.org/10.3390/pharmaceutics14081601.
10. H Kumar Manikyam, P Tripathi, S Balvant Patil, et al (2022). Extraction, purification, and quantification of hesperidin from the immature Citrus grandis/maxima fruit Nepal cultivar, *Asian Journal of Natural Product Biochemistry*, 20(1), 21-26, Available at: https://smujo.id/jnpb/article/view/10951/5907.
11. J E Audia and R M Campbell (2016). Histone modifications and cancer, *Cold Spring Harbor Perspectives in Biology*, 8(4), Available at: https://doi.org/10.1101/cshperspect.a019521.

12. C Das and T K Kundu (2005). Transcriptional regulation by the acetylation of nonhistone proteins in humans – a new target for therapeutics, *IUBMB Life*, 57(3), 137-149, Available at: https://doi.org/10.1080/15216540500090629.
13. T Narita, B T Weinert and C Choudhary (2019). Functions and mechanisms of non-histone protein acetylation, *Nature Reviews Molecular Cell Biology*, 20(3), 156-174, Available at: https://doi.org/10.1038/s41580-018-0081-3.
14. J Huang, R Sengupta, A B Espejo, et al (2007). p53 is regulated by the lysine demethylase LSD1, *Nature*, 449(7158), 105-108, Available at: https://doi.org/10.1038/nature06092.
15. J Park, J Ho Lee, M La, et al (2007). Inhibition of NF-κB acetylation and its transcriptional activity by Daxx, *Journal of Molecular Biology*, 368(2), 388-397, Available at: https://doi.org/10.1016/j.jmb.2007.02.047.
16. A Scoumanne and X Chen (2008). Protein methylation: A new mechanism of p53 tumor suppressor regulation, *Histology and Histopathology*, 23(9), 1143-1149, Available at: https://doi.org/10.14670/hh-23.1143.
17. A Patil, N Munot, M Patwekar, et al (2022). Encapsulation of lactic acid bacteria by lyophilisation with its effects on viability and adhesion properties, *Evidence-Based Complementary and Alternative Medicine*, 2022, Available at: https://doi.org/10.1155/2022/4651194.
18. A Sarjerao Nalawade, R Vithoba Gurav, A Ravsaheb Patil, et al (2022). A comprehensive review on morphological, genetic and phytochemical diversity, breeding and bioprospecting studies of genus Chlorophytum Ker Gawl. from India, *Trends in Phytochemical Research*, 6(1), 19-45, Available at: https://tpr.shahrood.iau.ir/article_690150_848ddcaeeca5f791544ff5c682096c1c.pdf.
19. A Patil, S Balkundhi, H Joshi, et al (2011). Mehsana buffalo milk as prebiotics for growth of lactobacillus, *International Journal of Pharmacy and Pharmaceutical Research*, 1(1), 114-117, Available at: https://ijppr.humanjournals.com/wp-content/uploads/2022/10/17.-Mehsana-buffalo-milk-as-prebiotics-for-growth-of-Lactobacillus.pdf.
20. B Sung, M K Pandey, K Seok Ahn, et al (2008). Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis, *Blood*, 111(10), 4880-4891, Available at: https://doi.org/10.1182/blood-2007-10-117994.
21. J S You and P A Jones (2012). Cancer genetics and epigenetics: two sides of the same coin?, *Cancer Cell*, 22(1), 9-20, Available at: https://doi.org/10.1016/j.ccr.2012.06.008.
22. S B Baylin and P A Jones (2011). A decade of exploring the cancer epigenome - biological and translational implications, *Nature Reviews Cancer*, 11(10), 726-734, Available at: https://doi.org/10.1038/nrc3130.
23. A Kazanets, T Shorstova, K Hilmi, et al (2016). Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential, *Biochimica et Biophysica Acta*, 1865(2), 275-288, Available at: https://doi.org/10.1016/j.bbcan.2016.04.001.
24. R Kanwal and S Gupta (2012). Epigenetic modifications in cancer, *Clinical Genetics*, 81(4), 303-311, Available at: https://doi.org/10.1111/j.1399-0004.2011.01809.x.
25. M R Hassler and G Egger (2012). Epigenomics of cancer - emerging new concepts, *Biochimie*, 94(11), 2219-2230, Available at: https://doi.org/10.1016/j.biochi.2012.05.007.
26. F Crea, R Danesi and W L Farrar (2009). Cancer stem cell epigenetics and chemoresistance, *Epigenomics*, 1(1), 63-79, Available at: https://doi.org/10.2217/epi.09.4.
27. C Zeller and R Brown (2010). Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer, *Therapeutic Advances in Medical Oncology*, 2(5), 319-

329, Available at: https://doi.org/10.1177/1758834010375759.
28. C Farhy, S Hariharan, J Ylanko, et al (2019). Improving drug discovery using image-based multiparametric analysis of the epigenetic landscape, *Elife*, 8, Available at: https://doi.org/10.7554/elife.49683.
29. J Achinger-Kawecka, F Valdes-Mora, P-Loi Luu, et al (2020). Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer, *Nature Communications*, 11(1), Available at: https://doi.org/10.1038/s41467-019-14098-x.
30. T Zhang, A Pilko and R Wollman (2020). Loci specific epigenetic drug sensitivity, Nucleic Acids Research, 48(9), 4797-4810, Available at: https://doi.org/10.1093/nar/gkaa210.
31. P A Jones, J-Pierre J Issa and S Baylin (2016). Targeting the cancer epigenome for therapy, *Nature Reviews Genetics*, 17(10), 630-641, Available at: https://doi.org/10.1038/nrg.2016.93.
32. S Tiash and E Hoque Chowdhury (2015). Growth factor receptors: promising drug targets in cancer, *Journal of Cancer Metastasis and Treatment*, 1(3), 190-200, Available at: https://f.oaes.cc/xmlpdf/f88077b1-0f09-43c1-9f54-65bec0309f03/1192.pdf.
33. J Yang, J Nie, X Ma, et al (2019). Targeting PI3K in cancer: mechanisms and advances in clinical trials, *Molecular Cancer*, 18(1), Available at: https://doi.org/10.1186/s12943-019-0954-x.
34. L Fuino, P Bali, S Wittmann, et al (2003). Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B, *Molecular Cancer Therapeutics*, 2(10), 971-984, Available at: https://pubmed.ncbi.nlm.nih.gov/14578462/.
35. N Das, N Ray, A R Patil, et al (2022). Inhibitory effect of selected Indian honey on colon cancer cell growth by inducing apoptosis and targeting the β-catenin/Wnt pathway, *Food & Function*, 13(15), 8283-8303, Available at: https://doi.org/10.1039/d1fo03727g.
36. A Patil, V Mali and A Mali (2021). The diverse cytotoxicity evaluation of lactobacillus discovered from sheep milk, *Acta Scientific Pharmaceutical Sciences*, 5(12), 69-70, Available at: https://www.actascientific.com/ASPS/pdf/ASPS-05-0825.pdf.
37. A. Patil, J Intru Disouza and S. Pawar (2018). Probiotic potential of Lactobacillus plantarum with the cell adhesion properties. Journal of Global Pharma Technology. 10(12), 1-6, Available at: https://www.researchgate.net/publication/329732477_Probiotic_potential_of_Lactobacillus_plantarum_with_the_cell_adhesion_properties.
38. A Patil, S Pawar and J Disouza (2018). Granules of unistrain lactobacillus as nutraceutical antioxidant agent, *International Journal of Pharmaceutical Sciences and Research*, 9(4), 1594-1599, Available at: https://www.researchgate.net/publication/329311780_GRANULES_OF_UNISTRAIN_LACTOBACILLUS_AS_NUTRACEUTICAL_ANTIOXIDANT_AGENT.
39. A Patil, V Mali and R Patil (2020). Banana fibers camouflaging as a gut worm in a 6-month-old infant, *Iberoamerican Journal of Medicine*, 2(3), 245-247, Available at: https://doi.org/10.5281/zenodo.4125436.

CITE THIS ARTICLE

Abhinandan Patil et al. (2023). The Role of Epigenetic Modifications in Drug Response and Resistance, *Journal of Pharmacological Research and Developments*, 5(2), 25-35.